Biocon and Amylin Pharmaceuticals have entered into a joint agreement to develop, commercialise and manufacture a novel peptide therapeutic for the treatment of diabetes.

The research jointly conducted by the two companies will be based around Amylin’s “phybrid” technology.

Under the terms of the agreement, Amylin will provide expertise in peptide hormone development, particularly in the area of phybrid technology, as well as metabolic disease therapeutics.

Biocon will provide expertise in recombinant microbial expression to manufacture the compound and also leverage its experience in pre-clinical and clinical development of diabetes products.

Amylin president and CEO Daniel Bradbury said that this programme could unleash the potential of cutting-edge peptide science to transform the lives of patients with diabetes.

“We are pleased to work with Biocon and look forward to collaborating with them on this exciting programme,” Bradbury said.